Naratriptan

Major congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3553
R7065		 Yusuf (Control exposed to Sumatriptan), 2018 Major birth defects 1st trimester retrospective cohort (claims database) exposed to other treatment, sick Adjustment: No 0.13 [0.01;2.07] C 0/93   65/1,608 65 93
ref
S3523
R6968		 Spielmann (Control mainly exposed other treatments, sick), 2017 Major birth defects during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.85 [0.11;6.68] C
excluded (control group) 		1/42   12/429 13 42
ref
S3524
R6969		 Spielmann (Control unexposed, disease free), 2017 Major birth defects during pregnancy (anytime or not specified) excluded prospective cohort unexposed, disease free Adjustment: No 0.82 [0.11;6.11] C
excluded (exposition period) 		1/42   44/1,526 45 42
ref
S3489
R6727		 Ephross (Naratriptan versus Sumatriptan), 2014 Major birth defects (live birth, fetal death and induced abortions) 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.51 [0.07;3.88] C 1/46   20/478 21 46
ref
Total 2 studies 0.31 [0.06;1.63] 86 139
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Yusuf (Control exposed to Sumatriptan), 2018Yusuf, 2018 1 0.13[0.01; 2.07]659335%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ephross (Naratriptan versus Sumatriptan), 2014Ephross, 2014 2 0.51[0.07; 3.88]214665%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.31[0.06; 1.63]861390.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Control exposed to Sumatriptan; 2: Naratriptan versus Sumatriptan;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.31[0.06; 1.63]861390%NAYusuf (Control exposed to Sumatriptan), 2018 Ephross (Naratriptan versus Sumatriptan), 2014 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 0.31[0.06; 1.63]861390%NAYusuf (Control exposed to Sumatriptan), 2018 Ephross (Naratriptan versus Sumatriptan), 2014 2 Tags Adjustment   - No  - No 0.31[0.06; 1.63]861390%NAYusuf (Control exposed to Sumatriptan), 2018 Ephross (Naratriptan versus Sumatriptan), 2014 2 All studiesAll studies 0.31[0.06; 1.63]861390%NAYusuf (Control exposed to Sumatriptan), 2018 Ephross (Naratriptan versus Sumatriptan), 2014 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3523

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.31[0.06; 1.63]861390%NAYusuf (Control exposed to Sumatriptan), 2018 Ephross (Naratriptan versus Sumatriptan), 2014 20.510.01.0